Boston, MA 09/02/2014 (wallstreetpr) – GE Healthcare, a division of General Electric Company (NYSE:GE), recently made an announcement that the European Commission gave its nod for marketing of VIZAMYL™, a flutemetamol (18F) solution for injection. The European Commission gave marketing authorisation for VIZAMYL™ as the radio-pharmaceutical medicinal merchandise, which has been directed for use of Positron Emission Tomography Imaging in brains of adult patients suffering from Alzheimer’s disease (AD).
European Commission’s Nod for VIZAMYL™ in AD
VIZAMYL™ shall be used or directed towards PET imaging of especially beta amyloid neuritic plaque density in patients’ brains. The patients having cognitive impairment and being evaluated for AD along with other kinds of cognitive impairments shall be eligible for this.
It must be noted that VIZAMYL™ is an only PET imaging tracer used to detect amyloid, being given approval in Europe for colored images’ interpretation. It shall be available in a few European countries on a commercial basis starting 2015. VIZAMYL™ is primarily a diagnostic instrument and needs to be used along with clinical evaluation as well.
Statement from GE Healthcare
The President and CEO of Life Sciences, General Electric Company (NYSE:GE), Kieran Murphy called Dementia as a primary largest health as well as societal challenge across the globe. He added that getting a green signal for marketing authorisation of VIZAMYL™ in the EU would help the company in meeting challenges as well as assisting faster diagnostics of Alzheimer’s disease.
Mr. Murphy also said that the approval shall offer the physicians a crucial tool in the EU in order to find out about the Alzheimer’s disease in a few patients and at the same time, will also help in enhancing the future research process of disease modification elements.
Statement from the Alzheimer Center at the VU University Medical Center
The Cognitive Neurology Professor as well as the Director, Alzheimer Center situated in VU University Medical Center, Amsterdam, Philip Scheltens. Meanwhile said that both dementia, as well as Alzheimer’s disease, are a continuous burden on the society and healthcare, which is why VIZAMYL™ will prove to be important for support, as well as guidance of future research in development of disease modification techniques.
